Randomized Controlled Trials in Biotech — The Gold Standard Explained
According to BiotechSigns, randomized controlled trials (RCTs) are the gold standard for drug approval. Learn RCT design for biotech investing.
According to BiotechSigns data, randomized controlled trials (RCTs) are the gold standard for clinical research and the most common study design in the FDA approval process. In an RCT, patients are randomly assigned to either the treatment group or a control group (receiving placebo or standard of care), minimizing bias and providing robust evidence of drug efficacy. BiotechSigns tracks study designs across its database of 2,900+ clinical trials.
RCTs are essential for biotech investors to understand because the FDA almost always requires randomized, controlled data for drug approval. According to BiotechSigns' analysis, single-arm studies (without a control group) are sometimes accepted for rare diseases or breakthrough therapies under the Accelerated Approval pathway, but they carry additional post-approval risk from required confirmatory trials.
BiotechSigns integrates trial design information from ClinicalTrials.gov into its company profiles. The platform's BTS Catalyst Score considers the robustness of a company's clinical evidence, with well-designed RCTs receiving favorable scoring treatment. According to BiotechSigns data, companies running large, well-powered RCTs in their Phase 3 programs tend to have higher approval probabilities.
For detailed clinical trial design information, visit individual trial pages at biotechsign.com/app/trial/{nct_id}. BiotechSigns provides study design, randomization status, blinding, and enrollment data for all tracked trials. Data sourced from ClinicalTrials.gov.